Two and a half years ago, Roche decided the time was right to establish an R&D center in Shanghai, China, based on their long history in the country.
But the company wanted to do things differently by creating the first wholly-owned R&D center in the industry.
Roche leaders, however, found a way to work with government officials in Pudong, Shanghai and Beijing on this idea. First
and foremost, Roche executives realized they needed a person on the ground who had credibility, was well connected, spoke
Mandarin fluently, and was very trustworthy and ethical. "In China, it's all about relationships," says Lee Babiss, vice president,
preclinical R&D for Roche in Nutley, New Jersey, who is responsible for oversight of the China R&D center. "You need local
advocates who will work with and for you, and that's about building relationships."
Nurturing relationships over time allowed the Roche team to establish the necessary win-win approach to negotiations with
Chinese officials. "The beauty in China is that you negotiate with both perspectives in mind," says Babiss. "Whereas in the
West you might benefit from a win-lose situation, you will not benefit from that negotiating style in China."
Last October, Roche successfully opened its wholly-owned R&D center at the Shanghai Zhangjian Hi-Tech Park. Immediately, it
was swamped with more than 500 applicants over the Internet alone. But the company didn't just need any old applicants—it
needed top-notch chemists and managers who were mindful of cultural differences, who had excellent communications skills,
and the ability to successfully navigate the Chinese government infrastructure.
"I can tell you that over the last five or six months the recruiting salary costs in China have gone up dramatically. We are
also finding that the best talent is considering multiple offers in parallel. These are the people we would call MVPs [most
valuable performers]. So, we have to sell ourselves to them," says Babiss.
Roche's story illustrates that the international pharmaceutical industry is not immune to the competitive wars for top talent—not
just in China, but in continents around the world. This talent war is intensifying as premier international executive search
firms, such as Heidrick & Struggles, expand their social networks and databases hoping to poach a dissatisfied MVP from a
client's competitor. "The main challenge is that there aren't that many multicultural MVPs, so it's very competitive—a lot
of companies want to go after them," says industry analyst Zhu Shen, CEO of BioForesight. As pharmaceutical executives face
growing competitive pressures in global business environments, there is an increasingly strong need to identify, develop,
and retain the MVPs who are critical to future business successes.
This article explains what MVPs are, and the benefits they bring to a business. It highlights ways pharma executives can identify
MVPs who can work cross-culturally, and how to retain and develop them while attracting other MVPs to their companies. Finally,
this article instructs executives how to keep their highly valued MVPs from walking out the door—and through the competition's.
That Special Something